Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer

Roche today announced that Kadcyla (trastuzumab emtansine or T-DM1), the latest targeted medicine from its HER2 franchise and its first antibody-drug conjugate, has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news